Lifespan opens new clinical trial site in collaboration with TriSalus

PROVIDENCE – Lifespan Corp. is activating a new clinical trial site at Rhode Island Hospital in collaboration with TriSalus Life Sciences, an oncology therapeutics company.

The new Pressure-Enabled Regional Immuno-Oncology clinical trial will study a new potential treatment for patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma.

“The activation of this clinical trial site and continued collaboration with TriSalus marks an important milestone in our efforts to offer local access to the latest in cancer research,” said Michael Henderson, vice president for research and chief research officer at Lifespan. “We look forward to building upon this partnership as a leading cancer research center in Rhode Island.”

The trial will study SD-101, an investigational drug delivered intravascularly by the TriNav Infusion System using the Pressure-Enabled Drug Delivery method of administration to determine whether this approach can improve the performance of systemic checkpoint inhibitors in treating patients with liver and pancreatic tumors.

- Advertisement -

This is the latest phase of Lifespan’s partnership with Colorado-based TriSalus. Earlier this year, the company announced the opening of an on-campus laboratory for immunotherapy research.

“Expanding the PERIO-02 trial to Lifespan’s campus is an exciting addition for both of our teams and, importantly, for patients across New England,” said Steven C. Katz, chief medical officer at TriSalus. “Broadening our collaboration allows us to go beyond the informative research currently underway to further study our multifaceted approach to potentially improve immune responses for people living with difficult-to-treat cancers.”

Claudia Chiappa is a PBN staff writer. You may contact her at